tradingkey.logo

Amarin Corporation PLC

AMRN
View Detailed Chart
14.750USD
+0.660+4.68%
Close 02/06, 16:00ETQuotes delayed by 15 min
306.77MMarket Cap
LossP/E TTM

Amarin Corporation PLC

14.750
+0.660+4.68%
Intraday
1m
30m
1h
D
W
M
D

Today

+4.68%

5 Days

-1.14%

1 Month

+7.74%

6 Months

-1.99%

Year to Date

+5.70%

1 Year

+29.02%

View Detailed Chart

Key Insights

Amarin Corporation PLC's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 112 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 12.00.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Amarin Corporation PLC's Score

Industry at a Glance

Industry Ranking
112 / 392
Overall Ranking
243 / 4521
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Positive

Amarin Corporation PLC Highlights

StrengthsRisks
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
Overvalued
The company’s latest PE is -3.53, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 4.18M shares, increasing 0.10% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 0.00 shares of this stock.

Analyst Rating

Based on 2 analysts
Hold
Current Rating
12.000
Target Price
-14.83%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Amarin Corporation PLC News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Amarin Corporation PLC Info

Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
Ticker SymbolAMRN
CompanyAmarin Corporation PLC
CEOBerg (Aaron D)
Websitehttps://amarincorp.com/
KeyAI